Scott D. Sandell, 10% Owner at Trevi Therapeutics, Inc. (TRVI), bought 7,161,052 shares at $1.90 ($13.6M) on 2022-04-11, disclosed to the SEC on 2022-04-13.
Open-market purchase of $13.6M TRVI by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.90 | 948,948 | $1.8M | 13.3% |
| 2 | $1.90 | 948,948 | $1.8M | 13.3% |
| 3 | $1.90 | 2,631,578 | $5.0M | 36.7% |
| 4 | $1.90 | 2,631,578 | $5.0M | 36.7% |
| Total | $1.90 avg | 7,161,052 | $13.6M | 100% |
| Filing → |
| NEUE | SELL | 2025-10-06 | $25K | — | Filing → |
| MBX | BUY | 2024-09-17 | $8.0M | — | Filing → |
| KRRO | BUY | 2024-04-24 | $1000K | — | Filing → |